Sixty patients with symptomatic single-level lumbar degenerative disc disease were enrolled in the randomized double-blind study. They were put into four groups — low-dose cell intradiscal injections, high-dose cell intradiscal injection, vehicle alone and placebo.
After 52 weeks, patients in the high-dose cell group had a mean visual analog scale decrease of 62.8% from their baseline. The high-dose group was the only one to have a significant change in disc volume with mean increases of 249 millimeters at 52 weeks.
The low-dose and placebo groups didn’t have significant improvements in their VAS scores, and the vehicle group had a smaller significant decrease.
The study concluded, “High-dose allogeneic disc progenitor cells produced statistically significant, clinically meaningful improvements in back pain and disc volume at one year following a single intradiscal injection and were safe and well tolerated. These improvements were maintained at two years post-injection.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
